Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical Considerations.
Oncol Ther
; 9(1): 225-238, 2021 Jun.
Article
em En
| MEDLINE
| ID: mdl-33428085
ABSTRACT
ABP 980 (KANJINTI™, Amgen, Thousand Oaks, CA, USA; Amgen Europe B.V., The Netherlands) is a biosimilar to trastuzumab (Herceptin®), a monoclonal antibody that selectively binds human epidermal growth factor receptor-2 (HER2). Here we provide a brief overview of the totality of evidence (including analytical [structural and functional] characterization, nonclinical evaluation, and human pharmacokinetic [PK], pharmacodynamic, and clinical assessment comparing ABP 980 with trastuzumab reference product [RP]) that supported the approval of ABP 980, along with practical considerations on the reconstitution and use of the lyophilized product to ensure safe and effective administration. ABP 980 has been shown to be highly similar to the RP, with similar mechanism of action, binding, and potency. Key PK parameters, geometric means ratio (GMR [90% CI]) of Cmax and AUCinf, are comparable and within the equivalence margin of 0.80 to 1.25 (ABP 980 1.04 [0.99-1.08] versus trastuzumab US 1.06 [1.00-1.12]; ABP 980 0.99 [0.95-1.03] versus trastuzumab EU 1.00 [0.95-1.06]). No clinically meaningful differences were found between ABP 980 and RP in a comparative clinical trial in patients with HER2-positive early breast cancer. Pathological complete response-ABP 980 48% versus RP 41% (risk difference [RD], 90% CI 7.3%, 1.2-13.4; relative risk [RR], 90% CI 1.188, 1.033-1.366). Sensitivity analyses per central pathology review-ABP 980 48%; RP 42% (RD 5.8%, -0.5 to 12.0; RR 1.142, 0.993-1.312), with RD and RR falling within predefined equivalence margins. Similar to trastuzumab RP, KANJINTI™ is supplied as a sterile, lyophilized cake to be reconstituted with bacteriostatic water for injection (BWFI) for multiple-dose injection or sterile WFI for single use. Stability data support storage of reconstituted solution at 2-8°C (36-46°F), up to 28 days. Reconstituted solution can be diluted in infusion bags containing 0.9% saline and stored for up to 24 h prior to intravenous administration.
Texto completo:
1
Bases de dados:
MEDLINE
Tipo de estudo:
Etiology_studies
Idioma:
En
Revista:
Oncol Ther
Ano de publicação:
2021
Tipo de documento:
Article
País de afiliação:
Alemanha